Versant Ventures VII GP, L.P. - 10%+ Owner at Lycia Therapeutics, Inc.

Issuer-level insider activity

Identity Names, identifiers, and filing context for this profile. 1 identity field
Entity type
Company
Source evidence Original filing metadata and source links for verification. 1 source field
Source filing history
Open source filing history

No buys or sells have been reported by Versant Ventures VII GP, L.P. since 16 Nov 2025

Reported holdings for Versant Ventures VII GP, L.P. in Lycia Therapeutics, Inc.

Form 4 holding 10%+ Owner

Lycia Therapeutics, Inc.

Security class
Series A Preferred Stock
Shares / value
0
Estimated value
Report date
26 Oct 2026
Price
Ownership
Indirect
Underlying class
Common Stock
Underlying amount
Form 4 holding 10%+ Owner

Lycia Therapeutics, Inc.

Security class
Series A Preferred Stock
Shares / value
0
Estimated value
Report date
26 Oct 2026
Price
Ownership
Indirect
Underlying class
Common Stock
Underlying amount
Form 4 holding 10%+ Owner

Lycia Therapeutics, Inc.

Security class
Series A Preferred Stock
Shares / value
0
Estimated value
Report date
26 Oct 2026
Price
Ownership
Indirect
Underlying class
Common Stock
Underlying amount
Form 4 holding 10%+ Owner

Lycia Therapeutics, Inc.

Security class
Series A Preferred Stock
Shares / value
0
Estimated value
Report date
26 Oct 2026
Price
Ownership
Indirect
Underlying class
Common Stock
Underlying amount
Form 4 holding 10%+ Owner

Lycia Therapeutics, Inc.

Security class
Series A Preferred Stock
Shares / value
0
Estimated value
Report date
26 Oct 2026
Price
Ownership
Indirect
Underlying class
Common Stock
Underlying amount
Form 4 holding 10%+ Owner

Lycia Therapeutics, Inc.

Security class
Series A Preferred Stock
Shares / value
0
Estimated value
Report date
26 Oct 2026
Price
Ownership
Indirect
Underlying class
Common Stock
Underlying amount
Form 4 holding 10%+ Owner

Lycia Therapeutics, Inc.

Security class
Series B Preferred Stock
Shares / value
0
Estimated value
Report date
26 Oct 2026
Price
Ownership
Indirect
Underlying class
Common Stock
Underlying amount
Form 4 holding 10%+ Owner

Lycia Therapeutics, Inc.

Security class
Series B Preferred Stock
Shares / value
0
Estimated value
Report date
26 Oct 2026
Price
Ownership
Indirect
Underlying class
Common Stock
Underlying amount
Form 4 holding 10%+ Owner

Lycia Therapeutics, Inc.

Security class
Series B Preferred Stock
Shares / value
0
Estimated value
Report date
26 Oct 2026
Price
Ownership
Indirect
Underlying class
Common Stock
Underlying amount
Form 4 holding 10%+ Owner

Lycia Therapeutics, Inc.

Security class
Series B Preferred Stock
Shares / value
0
Estimated value
Report date
26 Oct 2026
Price
Ownership
Indirect
Underlying class
Common Stock
Underlying amount
Form 4 holding 10%+ Owner

Lycia Therapeutics, Inc.

Security class
Series B Preferred Stock
Shares / value
0
Estimated value
Report date
26 Oct 2026
Price
Ownership
Indirect
Underlying class
Common Stock
Underlying amount
Form 4 holding 10%+ Owner

Lycia Therapeutics, Inc.

Security class
Series B Preferred Stock
Shares / value
0
Estimated value
Report date
26 Oct 2026
Price
Ownership
Indirect
Underlying class
Common Stock
Underlying amount

Transaction history for Versant Ventures VII GP, L.P. in Lycia Therapeutics, Inc.

Sym Class Transaction % SEC-reported value SEC-reported price Shares Shares after Date Ownership
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .